Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia's product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects.
In addition to Eupraxia’s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
In addition to Eupraxia’s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
Location: Mexico, Tamaulipas, Ciudad Victoria
Employees: 11-50
Total raised: $30M
Founded date: 2012
Investors 1
| Date | Name | Website |
| - | adMare Bio... | admarebio.... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.03.2024 | - | $30M | - |
Mentions in press and media 8
| Date | Title | Description |
| 15.03.2024 | Eupraxia Pharmaceuticals Announces Closing of Overnight Marketed Offering for Gross Proceeds of C$33.9 Million | - |
| 13.03.2024 | Eupraxia Pharmaceuticals Makes a Bold Move | Eupraxia Pharmaceuticals Inc., a biotech company on the rise, has set the stage for a game-changing move. With an overnight marketed public offering of approximately $30 million, the company is gearing up for a significant financial boost. ... |
| 12.03.2024 | Eupraxia Pharmaceuticals Announces Pricing of Overnight Marketed Offering of $30 Million | - |
| 11.03.2024 | Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million | - |
| 11.03.2024 | Eupraxia Pharmaceuticals Announces Overnight Marketed Offering of Approximately $30 Million | NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES VICTORIA, British Columbia, March 11, 2024 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a clini... |
| 22.06.2021 | EUPRAXIA PHARMACEUTICALS INC. Eupraxia Pharmaceuticals Inc :. Announces $10 Million Convertible Debt Agreement with Silicon Valley Bank and Conversion of $6.0 Million pre-IPO Debt | VICTORIA, BC, June 21, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today anno... |
| 16.06.2021 | EUPRAXIA PHARMACEUTICALS INC. Eupraxia Pharmaceuticals Inc :. Announces Presentation at the Raymond James Human Health Innovations Conference | VICTORIA, BC, June 16, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today anno... |
| 14.04.2021 | EUPRAXIA PHARMACEUTICALS INC. Eupraxia Pharmaceuticals Inc :. to Present at Bloom Burton & Co. Healthcare Investor Conference | VICTORIA, BC, April 13, 2021 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX), a Phase 2 clinical-stage biotechnology company with an innovative drug delivery technology platform, today ann... |